InvestorsHub Logo
Followers 275
Posts 32725
Boards Moderated 0
Alias Born 11/14/2013

Re: None

Wednesday, 01/06/2016 9:12:41 PM

Wednesday, January 06, 2016 9:12:41 PM

Post# of 703188
Beartrap, did you possibly talk to Dr. Bosch about IL-8? He has known for at least 2 years that increased IL-6, IL-8 and TNF-a were a powerful combination, but LP mentioned in her London conference that the IL-8 correlation with survival was probably unexpected for some.

I don't know if people recognize this, but the DCVax-Direct program was talked about for about a decade or so before the phase I clinical trial began -- even though the company knew how great its potential was.

My thinking is that Dr. Bosch took Dr. Triozzi's words from a decade and a half ago to heart:

IT DC therapy has potential advantages over alternate approaches. It avoids the necessity of identifying a specific tumor-associated antigen while increasing the spectrum of relevant antigens available for presentation. IT DC therapy may be applied practically in a variety of clinical situations, including patients with small tumors. Several issues will need to be addressed before this approach becomes clinically useful. Although an immune response to HSP-associated tumor antigens may be operational, the mechanism of the tumor regressions observed and the mechanism of failure will require further study. It is possible that DCs in other states of differentiation may be more effective after IT injection. More importantly, whether or not the antitumor immunologic activity observed in situ can be expanded systemically will need to be established. -- Dr. Triozzi



I'd highlight some words or phrases above, but I think the entire passage (every thought) stands on its own. It is, in my estimation, extremely prescient, and I believe Dr. Bosch and colleagues devoted a number of preclinical years to fulfill Dr. Triozzi's premise and heed his advice.

LP had to "buy" science time, and there is no question some can attempt to paint her as a charlatan. Instead, I'd suggest she is a critical member of the team engaged in developing a new field.

This ain't no fast food, but then, I've always appreciated slow cooking.

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News